Connect Sign In
The FDA and the National Comprehensive Cancer Network (NCCN) urge DPYD testing before chemotherapy. ARUP offers guidance and resources to help clinicians choose and interpret genotyping tests.
ARUP experts will highlight the latest in genomic sequencing at the upcoming National Society of Genetic Counselors (NSGC) Annual Conference.
An article describing ARUP’s validation of an artificial intelligence (AI) solution to detect gastrointestinal parasites in wet mounts has been published in the Journal of Clinical Microbiology.
ARUP supports Breast Cancer Awareness Month with advanced testing, BRCA1 and BRCA2 expertise, and local blood donations that benefit patients in Utah.
ARUP’s central pathology review service has provided key support for the Cogent SUMMIT trial through robust laboratory testing, mastocytosis pathology expertise, and rigorous quality standards.
ARUP has launched a highly sensitive and fully automated molecular assay to detect hepatitis delta virus (HDV) that will facilitate better detection of the virus.
At upcoming conferences, ARUP experts will highlight a new blood-based biomarker assay for Alzheimer’s disease and share a presentation on building a successful laboratory outreach program.
ARUP experts have received recognition from ADLM and the ADLM Academy for their remarkable achievements this year, winning Young Investigator Merit and Distinguished Abstracts awards.
A patient’s insistence on DPYD genotyping before chemotherapy highlights growing support for broader testing to prevent severe or fatal drug toxicity in patients.
The latest edition offers a look at ARUP’s advancements in the use of artificial intelligence for ova and parasite testing, highlights the importance of genetic testing, and features lifesaving tests.
